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ABSTRACT 
Background 
Guidelines for investigation of perioperative drug allergy exist, but the quality of services is 
unknown.  Specialist perioperative anaphylaxis services were surveyed through the Royal College of 
Anaesthetists 6th National Audit Project. 
Objectives 
We compare self-declared UK practice in specialist perioperative allergy services with national 
recommendations. 
Methods 
A SurveyMonkeyTM questionnaire was distributed to providers of allergy services in the 
UK.  Responses were assessed for adherence to the best practice recommendations of the British 
Society for Allergy and Clinical Immunology, the Association of Anaesthetists of Great Britain and 
Ireland and the National Institute for Health and Care Excellence (NICE) Guidance on Drug Allergy - 
CG183. 
 3 
 
Results 
Over 1200 patients were evaluated in 44 centres annually.  Variation in workload, waiting times, 
access, staffing and diagnostic approach was noted.  Paediatric centres had the longest routine 
waiting times (most wait >13 weeks) in contrast to adult centres (most wait <12 weeks).  Service 
leads are allergists/immunologists (91%) or anaesthetists (7%). 
Potentially important differences were seen in: testing repertoire [10/44 (23%) lacked BSACI 
compliant NMBA panels and 17/44 (39%) lacked a NAP6-defined extended panel; many failed to 
screen all cases for chlorhexidine 19/44 (43%) or latex 21/44 (48%)], staffing [only 26/44 (59%) had 
specialist nurses and 18/44 (41%) an anaesthetist], and provision of information [18/44 (41%) gave 
immediate information in clinic, and 5/44 (11%) on support groups].  
Most centres were able to provide diagnostic challenges to antibiotics [40/44 (91%]) and local 
anaesthetics [41/44 (93%)]. 
Conclusions and Clinical Relevance 
 
Diagnostic testing is not harmonised, with marked variability in the NMBA panels used to identify 
safe alternatives.  Chlorhexidine and latex are not part of routine testing in many centres.  
Poor access to services and patient information provision require attention.  Harmonisation of 
diagnostic approach is desirable, particularly with regard to a minimum NMBA panel for 
identification of safe alternatives.   
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INTRODUCTION 
National Guidelines exist for the investigation and management of drug allergy, including in the 
perioperative setting [1] [2] [3].  The incidence of perioperative anaesthetic anaphylaxis is uncertain, 
and access to Specialist allergy services in the UK outside of London and the South East of England 
has been noted to be patchy and poorly harmonised in the approach to diagnosis and management 
[4].  There are also NHS national specialist services definitions for allergy B9 and E09 [5][6].  This 
survey of the provision of specialist perioperative allergy centres was conducted as part of the Royal 
College of Anaesthetists (RCoA) 6th National Audit Project (NAP6), studying perioperative 
anaphylaxis. It aims to describe the provision and practice of specialist allergy services for 
perioperative anaphylaxis in the UK. 
METHODS 
A SurveyMonkeyTM questionnaire to ascertain availability, workload and practice in centres providing 
the specialist assessment of perioperative allergy in the UK was devised (Supplementary material 1) 
and distributed to all potential providers of perioperative allergy services in the UK.  Sixty-five 
potential providers were contacted through triangulation of clinic lists from the British Society for 
Allergy and Clinical Immunology (BSACI), the British Society for Immunology (BSI), Allergy UK, the 
Anaphylaxis Campaign, both Royal Colleges of Pathologists and Physicians, the professional networks 
known to the panel and the UK Immunology and Allergy Nursing Group.  Of these, 44 separate 
centres declared such activity and there are no other known UK specialist clinics with a significant 
workload who have not responded yet are known to the panel. This survey was distributed between 
December 2015 and April 2016 and services were asked to provide data relating to the previous 12 
months. Where discrepancies or uncertainties were identified in the data, the centres were 
contacted again for clarification by email. 
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The SurveyMonkeyTM data were exported to a spread sheet for descriptive analysis. No formal 
statistical analysis was undertaken.  Where necessary, additional clarification of responses was 
sought from centres subsequently. 
Based on responses, adherence to recommendations derived from the BSACI [1], the Association of 
Anaesthetists of Great Britain and Ireland (AAGBI) and the National Institute for Clinical Excellence 
(NICE) CG183 [3] guidance was assessed as follows: 
National Institute for Clinical Excellence (NICE) G183 Recommendations (N) 
N1 Allergy specialists should give the following written information to people who have undergone 
specialist drug allergy investigation:  
N1.1 the diagnosis  ? whether they had an allergic or non-allergic reaction  
N1.2 the drug name and a description of their reaction 
N1.3 the investigations used to confirm or exclude the diagnosis  
N1.4 drugs or drug classes to avoid in future  
N1.5 any safe alternative drugs that may be used  
N2 Providing information and support to patients  
N2.1 provide structured written information ŽŶƉĞƌƐŽŶ ?ƐƐƵƐƉĞĐƚĞĚĚƌƵŐĂůůĞƌŐǇ.  
British Society for Clinical Immunology and Allergy (BSACI) Recommendations (B) 
B1 Referral should be made to a major allergy centre with expertise in drug allergy and high 
throughput of anaesthetic anaphylaxis because of the need for experience in interpreting tests and 
the serious consequences of diagnostic error.  
B2 The centre should be able to investigate all potential causes. This involves a range of drug 
classes/substances including:  
B2.1 neuromuscular blocking agents (NMBAs) 
B2.2 intravenous anaesthetics 
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B2.3 antibiotics 
B2.4 opioid analgesics 
B2.5 non-steroidal anti-inflammatory drugs (NSAIDs) 
B2.6 local anaesthetics (LAs) 
B2.7 latex  
B2.8 skin antiseptics (we used chlorhexidine as a surrogate for this) 
B3 Investigation should be in a dedicated drug allergy clinic 
B4 Stepwise investigation is necessary and depends on the likely cause, but a suspected IgE-
mediated reaction (e.g. NMBAs, i.v. anaesthetics, antibiotics, latex) requires  
B4.1 skin testing and 
 B4.1 in some cases drug challenge 
 B5 The aim of the investigation should be to identify the cause of anaphylaxis and to recommend a 
range of drugs/agents likely to be safe for future use. 
B6 The allergist is responsible for a detailed report to the referring doctor and GP, and a shorter 
ƌĞƉŽƌƚĂŶĚƉƌŽǀŝƐŝŽŶŽĨ ?ŵĞĚŝĐĂůĂůĞƌƚ ?ǁŽƌĚŝŶŐƚŽƚŚĞƉĂƚŝĞŶƚ 
B7 Role of the anaesthetist - Report to MHRA 
B8 Role of the allergist  
B8.1 Identify the cause of the reaction 
B8.2Identify drugs likely to be safe for future anaesthesia 
B8.3 Provide a written report to referring consultant, copied to GP and surgeon 
B8.4 WƌŽǀŝĚĞƉĂƚŝĞŶƚǁŝƚŚĂďƌŝĞĨ ?ƚŽǁŚŽŵŝƚŵĂǇĐŽŶĐĞƌŶ ?ůĞƚƚĞƌ ?ůŝƐƚŝŶŐƚŚĞĂďŽǀĞ ? 
B8.5 Provide ƉĂƚŝĞŶƚǁŝƚŚĂŶ ?ůĞƌƚ ?ĂƉƉůŝĐĂƚŝŽŶĂŶĚƚŚĞƐƉĞĐŝĨŝĐǁŽƌĚŝŶŐƚŽďĞŝŶƐĐƌŝďĞĚ 
B8.6 Report to MHRA 
B9 The presence of a clinic nurse with specialist allergy experience 
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AAGBI Recommendations (A) 
A1 Cases of anaphylaxis occurring during anaesthesia should be reported to the Medicines Control 
Agency (Note: MHRA is now superseded by the Medicines Control Agency (MCA)) 
We arbitrarily defined  ?larger ? adult centres as those seeing A? 20 patients referred for investigation 
of perioperative hypersensitivity per year and  ?smaller ? centres as those seeing <20, to examine 
whether there were any differences in the services provided that clearly correlated with workload 
for standard B1.  
Some of the text of the guideline recommendations above are open to interpretation.  The 
guidelines state that the clinic should be able to investigate all causes, but are not specific about 
whether testing should occur in all cases to demonstrate lack of sensitisation or detect potential 
hidden exposure.  Therefore, the NAP6 panel agreed that for antiseptics (chlorhexidine in most 
cases) the compliant clinic would be able to test, but we have also noted where the testing was 
applied to all, or only selected cases since this is often a hidden allergen. The same approach was 
used for latex testing. We have noted where centres were able to test to B2.1 -2.8 inclusively as 
evidence of full repertoire testing.  
Similarly, where NMBA use was assessed (standard B2.1), the centre was deemed compliant where 
the ability to test for NMBAs was offered, and we separately assessed if panels of NMBAs included 
all of the following (the agreed NAP6 minimum panel (see below) and referenced to standard N1.4, 
N1.5, B2.1, B5, B8.2). 
dŚĞ ?EW ?ŵŝŶŝŵƵŵƉĂŶĞů ?ǁĂƐ defined as: the suspected NMBA; at least one alternative in the 
same class; inclusion of suxamethonium and rocuronium (to identify a safe agent for rapid sequence 
induction); inclusion of atracurium or cis-atracurium.  If the suspected culprit drug is one of those 
agents, then the minimum panel would consist of 4 agents.  Vecuronium, pancuronium and 
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mivacurium have either not been available at times during the survey period or are so infrequently 
used that it their use was not deemed mandatory for compliance with the  ?NAP6 panel ?. 
For MDT related data (mandated in the National Specialist Services Contracts for Allergy B9 and E9) 
[5, 6], we defined an MDT as a face-to-face or telephonic/video-conferenced multidisciplinary 
meeting with at least two medical and/or nursing specialties present. We did not count clinics where 
two or more specialties were present but where the respondents did not report an MDT in the MDT 
specific question. 
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RESULTS 
We identified approximately 50 centres providing adult, paediatric or mixed perioperative allergy 
testing services. The survey was sent to all centres and evaluable responses were received from 47.  
One respondent submitted no data so was excluded from analysis, and two other services submitted 
duplicate entries, which were excluded, leaving 44 evaluable responses.  Eleven services provided 
paediatric services alone. Adult services were available in 33 centres, of which five also saw a small 
number of children.  
Workload 
Sixteen adult centres and two paediatric centres reported actual numbers of patients seen and other 
centres estimated activity for the previous 12 months.  
Adult Centre Workload 
The 33 adult centres evaluated an estimated 1271 adult patients in the previous 12 months.  Of 
these; 21 (64%) investigated t20 patients per year (range 21-136; median 57 cases) and 12 (36%) 
saw <20 (median 10). Eleven (33%) adult cenƚƌĞƐƐĂǁA? ? ?ƉĂƚŝĞŶƚƐƉĞƌǇĞĂƌ. 
Ninety percent 1149/1271 of adult cases were investigated in larger centres (>20) and 10% 
(122/1237) in smaller centres (<20).   
Paediatric Centre Workload 
All paediatric centres saw <20 patients per year, with a median of 4 (range 1-9). Fifty-three children 
were investigated for suspected perioperative anaphylaxis over the previous 12 months  ? 46 in 
specialist paediatric centres and seven in the five combined adult/paediatric centres. 
Access 
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Considerable geographical variability in distribution of services is shown in Error! Reference source 
not found.  Regional variation in the number of services and referral patterns related to population 
size and density in Figure 1b. 
Compliance with standards 
 
Compliance with published standards for each aspect of patient care is presented in (Figure 2a-c). 
Overall the results showed little difference in compliance between larger, smaller or paediatric 
centres (Figure 2a-c) for most elements, but notable differences in approach to paediatric cases due 
to a perception of rarity of NMBA allergy in paediatric cases in some or a wish to avoid or limit 
distressing testing (like IDT) in most. As a result, few paediatric centres would strictly meet the BSACI 
standard of investigating all administered drugs or identifying several or a range of (herein assumed 
to be at least 2) alternatives. 
Standards with greatest variations in practice were the use of NMBA panels and anaesthetists in 
paediatric clinics, issuing of patient written and verbal information at the clinic visit, provision of 
information on patient support groups, availability of blood testing for drug specific IgE, routine use 
of testing to latex or chlorhexidine and direct reporting to MHRA by the clinic. 
Waiting Times 
Waiting times are shown in Figures 3a-c. 
Adult Centres 
Urgent appointments were available to most within five weeks (Figure 3a & b). Most adults were 
seen within 12 weeks routinely. Two centres breached current national waiting time targets of 18 
weeks  ? both were larger centres. 
There were no major differences in waiting times between larger and smaller centres.  
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Paediatric Centres 
Urgent appointments were available to most within eight weeks. Routine paediatric appointment 
waiting times were longer than adults with most waiting >13 weeks (Figure 3c). 
One centre breached current national targets with a wait of >18 weeks. 
Staffing 
Leadership 
Adult Centres 
The majority of services (28/33) are led by an allergist or immunologist, with three led by an 
anaesthetist, one by a respiratory physician and one did not declare a specialty lead.   
Of the 21 larger adult centres, 18 were allergist/immunologist-led, and three led by an anaesthetist 
with drug allergy experience.  Of the 12 smaller adult centres, nine are allergist/immunologist-led, 
one led by an anaesthetist with allergy experience and one by a respiratory physician experienced in 
allergy and one did not declare a specialty lead.    
Paediatric Centres 
All eleven centres are led by a paediatric allergist.  
Involvement of an anaesthetist 
Adult Centres 
Nine of 21 larger centres and five of 12 smaller centres reported involvement of an allergy-
experienced anaesthetist in the clinic. A total of 675/1271 (53%) adults were seen in a clinic 
including an allergy-experienced anaesthetist, of whom 626 (93%) were seen in the nine larger 
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centres. Two further centres (both larger centres) had an anaesthetist without extensive anaphylaxis 
experience and one reported both. 
Paediatric Centres 
One of eleven paediatric centres reported the involvement of an allergy-experienced anaesthetist. 
Overall, eighteen of 44 (41%) centres can be deemed to have appropriate anaesthetist involvement.  
Involvement of a nurse with drug allergy experience 
Sixty percent of all centres (26/44) had at least one nurse with drug allergy experience.  
Adult Centres 
Thirteen of 21 larger adult and six of 12 smaller adult centres had an experienced nurse. 
Paediatric Centres 
Seven of eleven paediatric centres had an experienced nurse. 
Involvement of a pharmacist to prepare drug dilutions 
Four centres reported the availability of pharmacy-led drug preparation for clinical investigations; in 
three larger adult centres and one paediatric centre.  
Operation of the service 
Adult Centres 
Face-to-face multi-disciplinary team meetings (MDTs) were more common in larger centres (12/21, 
57%) than smaller centres (4/12, 33%).  Two centres (one larger, one smaller) had an alternative 
arrangement to ensure MDT discussion (e.g. a telephone MDT before, during or after the clinic).   
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Three larger and one smaller adult centres reported presence of an anaesthetist in clinic, but no 
formal MDT.  
While 55% complied with a face-to-face or telephone MDT, if the presence of two specialties in a 
clinic is judged to be equivalent to an MDT then overall provision rises to 67%.  
Paediatric Centres 
Five paediatric centres had a face-to-face MDT arrangement (5/11, 45%). Two additional services 
performed clinics jointly with a paediatric allergist. Only one clinic was staffed by an anaesthetist 
experienced in drug allergy.  
Overall compliance with a face-to-face MDT standard in paediatric clinics was 45% and if the 
presence of two specialties in a clinic is judged to be equivalent to an MDT then overall compliance 
rises to 64%.   
Clinic Assessment 
Most adult patients (1262/1271, 99%) and all 53 paediatric cases were assessed by face-to-face clinic 
visits. 
Some larger centres offered additional remote diagnostic interpretation and triaging of cases.  Two 
larger adult centres reported additional initial laboratory interpretative investigation of acute 
reactions for 203 patients, some of whom may have subsequently been triaged to face-to-face clinic 
visits (information not available).  
Database 
Sixty-four percent of all centres reported keeping a database of anaesthetic adverse reaction cases: 
thirteen larger adult centres (62%), eight smaller adult centres (67%) and seven paediatric centre 
64%).  
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Referral pathways 
All but one clinic reported that they accept consultant-to-consultant referrals to enable rapid and 
direct assessment. 
Investigations 
Considerable variation in practice was revealed both in the repertoire and testing modalities across 
the survey centres.  Centres should be able to investigate all potential culprits in line with the 
standards above. 
Pholcodine testing 
Six larger adult centres, one smaller centre and one paediatric centre routinely query pholcodine 
exposure (8/44, 18%). There is no specific standard for testing against pholcodine, but it would be 
expected to be part of an expert centre ?s repertoire. 
Chlorhexidine testing 
Fifty-seven percent (25/44) of centres reported testing for chlorhexidine in all cases.  A further 16 
(36%) reported testing only those with known exposure.  Thus, 93% were compliant with the 
guidance for being able to assess this antiseptic. Compliance is summarised in Figure 2. 
Fourteen (67%) larger adult centres routinely tested for chlorhexidine and seven in selected cases 
only.  Six smaller (50%) adult centres routinely tested for chlorhexidine and four in selected cases 
only.  Five (45%) paediatric centres routinely tested and five only in selected cases. 
Reported testing protocols (Figure 4) varied.  Skin prick testing (SPT) was the most common first-line 
test (26/44) followed by serum specific immunoglobulin E (sIgE) (9/44), with intradermal testing 
(IDT) or sIgE commonly used for second-line testing in adults (IDT was rarely used in children).  One 
centre reported performing chlorhexidine challenges.  Nine centres reported the use of 
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chlorhexidine sIgE blood tests as a first-line test (seven of which would then do SPT as a second-line 
test).  Only one larger adult clinic used IDT as a first-line test (with sIgE test as a second-line test).  
Latex 
Twenty-three adult centres (14 larger; nine smaller, 70% overall) reported always testing for latex 
and nine more in selected cases.  SPT was the preferred first test for 20 (16 larger; four smaller) and 
sIgE for five (three larger; two smaller) centres.  Secondary testing was predominantly sIgE (eight 
centres) and IDT (three centres). Only larger adult centres used IDT for latex.  Compliance is 
summarised in Figure 2. 
Nine of eleven paediatric centres reported that they always test for latex and two in selected cases. 
Ten reported using SPT as first line testing; six reported using sIgE as a second line test and none 
reported using IDT. Five apparently only use a single modality of testing (four SPT, one sIgE) (Figure 
5).  
Neuromuscular Blocking Agents (NMBA) 
Panel testing and safe identification of alternative NMBA  
Practice was highly variable. Compliance is summarised in Figure 2 and Table 1. 
Adult Centres 
Most adult centres (32/33) reported using a  ?panel ? of agents containing many of the routinely 
available drugs when testing for NMBA allergy (Table 1) but the majority would only do so where the 
suspected NMBA was positive in initial skin testing. There is no definition of an appropriate panel in 
existing guidance, but the NAP6 authors agreed a harmonised  ?EW ?WĂŶĞů ?Ěefinition to meet the 
requirement of safe identification of alternative agents (see methods).   
Compliance is summarised in Figure 2 and Table 1.  Most adult centres initially test to the suspected 
culprit agent only, and all reported use of a panel of NMBAs, however one specifically would only 
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test to a couple of alternatives rather than the full panel or the NAP6 minimum panel.  A small 
number of larger centres reported that they routinely test extended NMBA panels in all, but most 
appeared to only use the panel where one of the suspected culprits was positive on initial screening.  
The agents reported to be used routinely in panels are summarised in Table 1 and is broadly 
comprehensive.   
Paediatric centres   
Five of eleven paediatric centres initially test to the suspected culprit agent only, while six reported 
use of a limited panel of NMBAs sequentially, of which only two included rocuronium and 
suxamethonium routinely.  However, all would only proceed to use the panel where the initial test 
was positive, and one centre specifically stated that NMBAs were rarely tested in children.  
Compliance is summarised in Figure 2. 
Suxamethonium was routinely used in panels by five paediatric centres but another commented that 
suxamethonium is rarely used in children and is therefore rarely part of the panel (Table 1).   
Testing strategies appeared consistent for NMBAs, with most reporting use of SPT first and then IDT 
if negative; one specified SPT only (Figure 6).  Several centres noted the need to minimise distressing 
IDT testing in children.  Few centres used sIgE to thiocholine (suxamethonium, and quaternary 
ammonium groups). One centre reported using sIgE followed by sequential SPT and IDT.   
Drug Challenges 
No centre performed challenges to NMBAs. Twenty-five of 44 (57%) centres perform challenges to 
antiemetics; eleven (25%) to hypnotics; 24 (55%) to anxiolytics; 34 (77%) to NSAIDs; 29 (66%) to 
opioids and 41 (93%) to local anaesthetics.   
Other challenges on offer include: heparin, latex, chlorhexidine, and paracetamol. 
All paediatric centres offered NSAID and local anaesthetic challenges. 
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Antibiotic Challenges 
Forty centres (91%) provide antibiotic challenges (20/21 larger adults centres; 8/12 smaller centres; 
11/11 paediatric centres).  
Waiting times for antibiotic challenges were reported to be under nine weeks for 21/44 (48%), more 
than three months in 12/43 (28%) of centres and were similar in all types of centre (Figure 7). 
Information 
Adherence to relevant guidelines is shown in Figure 2. 
Only half of adult centres give immediate information to the patient (10/21 larger, 5/12 smaller and 
3/11 paediatric centres). All centres, however, stated that the patient receives a copy of the clinic 
letter. Only five of 44 centres (11%) reported giving additional information on patient support 
groups (two smaller adult centres and three larger ones). 
Thirty-nine (89%) centres (19/21 larger adult; 11/12 smaller adult; 9/11 paediatric) issued Medical 
alert/hazard warning information to the patient.  
All adult and paediatric centres sent a clinic letter to the referring clinician, and all also sent this to 
the general practitioner. 
Copy letters to the surgeon where applicable (Figure 2a) were sent by 36 (82%) centres (18/21 
larger; 10/11 smaller; 8/11 paediatric centres).  
All centres reported that the clinic letter identified the culprit drug when found and all but one 
identified the nature of the reaction (Figure 2a and b).  Two (5%) centres did not routinely describe 
the clinical features of the reaction or the clinical tests performed in the clinic letters (Figure 2b). 
All adult clinic centres reported identifying the drugs or drug groups to avoid and suitable 
alternatives. 
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Only six centres reported that they provide details of the alternative diagnosis where IgE-mediated 
allergy was excluded (Figure 2b). 
MHRA reporting 
Eleven (25%) centres overall (5/21 larger adult, 3/12 smaller adult and 3/11 paediatric) reported 
directly to MHRA, the rest relying on the referring clinician to do this (Figure 2c). 
DISCUSSION 
This is the first UK survey specialist allergy centres evaluating perioperative anaphylaxis and provides 
important information on the availability and self-reported practice in these services, prior to NAP6 
case data collection. Where possible, practice has been mapped to UK recommendations [3] [1] [2]. 
Most activity occurred in adult centres, but we do not know if this reflects differences in adult or 
paediatric referral patterns or incidence of anaphylaxis or surgery.  Future analysis of cases reported 
to NAP6 will provide data on this. 
Forty-four widely distributed UK centres (33 adult and 11 paediatric) were identified, of which 21 
saw more than 20 adult patients per year, but paediatric services were small and inequitably 
distributed.  Two smaller adult centres subsequently ceased providing service in 2017 due to staff 
retirements (workload approximately 30 patients per annum) and one more may also have ceased 
operation.  There was wide variation in the number of cases seen in each region with respect to total 
regional population and population density (Figure 1). 
London and the Midlands have the greatest concentration of services and, in contrast to many other 
reports on allergy services, the urban areas of northern England appear to be well served.  
Provision of services is limited in Northern Ireland, Wales, Scotland, the East of England, the South 
West, the South East of England and the West Midlands.  Scotland has three adult centres and Wales 
and Northern Ireland only one each. Wales and Scotland appear to have only one paediatric centre 
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and Northern Ireland none. No services submitted paediatric returns from the Southwest or East of 
England. 
Paediatric centres and a few larger adult centres reported the greatest problems with access waiting 
times and therefore the relationship of staffing and resources appropriate to the workload may need 
to be explored further. Two thirds of children had to wait more than 12 weeks to be seen, while 
more than half of adults waited more than eight weeks to be seen which may impact on test 
sensitivity.  Drug sensitisation to chlorhexidine is known to be transient [7] so these delays in 
assessment run the risk of missing important sensitisations and compromising the diagnostic 
algorithm. 
Access to drug challenge services was also poor, with fewer than half the centres able to challenge 
to antibiotics within eight weeks.   
Both BSACI and AAGBI guidance mandate a sufficient workload to maintain expertise and 20 cases 
was designated by our NAP6 panel to be a reasonable minimum to achieve this [1] [2].  Future 
guidelines should agree a definition of the minimum workload.  Our pragmatic definition enabled a 
review of compliance with recommendations, by workload.  Only one third of centres see more than 
50 patients each year.  No paediatric service saw more than ten cases in a year.  Of note, we found 
no clear evidence that self-reported compliance with published guidance varied markedly between 
adult centres with larger and smaller workload except for the less frequent use of extended NMBA 
panels, or between adult and paediatric centres, with the exception of the provision of more limited 
range of testing in smaller centres and the fact that testing is limited in children to minimise painful 
investigations like IDT as well as the perception that NMBA allergy is rare in children.  NMBA panel 
use is the exception rather than the rule. Separate paediatric guidance may be needed in future, 
since most centres would therefore not be adherent to the suggested NAP6 minimum panel. 
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The NHS England National Specialist Service Definitions for allergy (B09 and E09) mandate hub and 
spoke networking, accreditation and working to NICE, BSACI, RCPCH and AAGBI guidance.  Smaller 
clinics and all paediatric clinics might benefit from being part of these governance networks where 
this is not already the case. 
As almost two thirds of centres already keep a record of their cases in a spreadsheet or database (a 
requirement of the Specialist Allergy Service Specifications), this provides the opportunity to support 
research in allergy.  A minimum dataset could usefully be defined by professional societies.  
Improved co-ordination of data collected would offer the opportunity of improved research in 
specialist allergy. 
Adherence to guidelines for testing modalities appears good overall in adults and most services 
appeared comprehensive in repertoire, consistent with current recommendations.   However, there 
was room for harmonisation of approach to NMBA, Latex and Chlorhexidine testing, and better 
patient information.  The current guidelines are not very specific regarding minimal acceptable test 
repertoire and the authors analysed several additional requirements (NAP6 NMBA panel and 
routinely testing for chlorhexidine) specifically to enable robust evaluation.  Future iterations of 
guidelines should consider being more specific to advance harmonisation of practice. 
The purpose of perioperative drug allergy testing is to identify the culprit drug, plus any cross-
reacting drugs to which the patient may also be allergic, thereby to identify safe drugs, particularly 
when several drugs were co-administered.  This should enable the centre to provide a list of drugs to 
avoid, a list of safe alternatives and a list of drugs that have been excluded as the cause of the 
allergic reaction. Not all centres used harmonised protocols for NMBA and routine testing for 
chlorhexidine and latex, but paediatric centres may have some valid reasons for differences. 
We noted marked variability in the adequacy of the NMBA panels used [3] [1] [2] when judged 
against the NAP6 minimum panel suggestions and this may raise concerns about adequacy of testing 
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 ? especially the identification of safe alternative NMBAs for rapid sequence induction of anaesthesia.  
Most centres reported they would only test an extended panel if the putative culprit was positive, 
consistent with current guidance, but this may create a risk of failure to identify NMBA allergy 
through false-negative testing should all other culprits be negative, or if the clinical picture was 
highly suspicious for NMBA allergy. It was not clear if all would proceed to panel testing if the 
original suspected culprit was negative, but several centres specifically commented that they would 
do so in those circumstances. 
Half of the centres apparently omitted some common drugs (particularly cis-atracurium and 
suxamethonium).  This could be a risk to patients, since not testing prevents detection of relevant 
sensitisations or cross-reactivity to select safe alternatives, or restricts future anaesthetic options for 
rapid sequence induction.  Practice in children may however be different, for practical reasons, and 
separate guidance may be needed. 
It is likely that specific guidance on this matter would be of benefit in future for adults too.  The 
NAP6 panel developed a minimum NMBA panel definition (NAP6 NMBA Panel) that met the 
requirements of safe future anaesthesia in all circumstances. Only 18% of paediatric, 56% of smaller 
adult and 86% of larger adult centres met the NAP6 minimal panel definition.  This panel could be 
considered for future adoption (potential culprit, an NMBA from a different class, and two agents 
with specific utility: rocuronium and suxamethonium). 
Auditing and understanding the best diagnostic algorithm will require harmonised practice in future.  
Communication with colleagues appears generally good. Communication with patients may be less 
good. Most centres reported that they were fully compliant with the recommendations of NICE 
CG183 regarding specific written information, however supply of immediate information to patients, 
written information to patients and information on patient support groups was incomplete on their 
returns (Figure 2b).   
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Reporting of allergy testing results to the MHRA by clinics is rare and this is usually deferred to the 
anaesthetist (Figure 2c).  
While MDT working is not in guidelines it is a national specialist commissioning standard.  Only half 
of the services had a face-to-face MDT to discuss cases.  Of concern, anaesthetists were involved in 
fewer than half of the specialist centres and very rarely in paediatric clinics.  Three adult services 
were led by anaesthetists. Anaesthetists have a key role in detecting non-allergic causes for the 
clinical presentations, understanding the normal adverse event profile of the drugs given, the 
confounding effects of polypharmacy and patient co-morbidity, advising on suitable future strategies 
for anaesthesia and ensuring that all likely causes have been considered [2].   More anaesthetists 
with an interest in allergy are needed, to promote learning and enhance service quality.   
Networking arrangements could be used to ensure anaesthetist involvement in MDT case 
discussions. 
The staffing of clinic services was very variable and may not meet specialist service 
recommendations and guidance.  Specialist nurses with allergy experience were missing in 36-50% of 
clinics. Pharmacist involvement in preparation of drug dilutions for skin tests or challenges was very 
infrequent, but would be desirable.  
Diagnostic testing practice must be harmonised. Definitive and translatable predictive values for any 
testing strategy or sequence remain unknown. Skin prick testing remains the initial test of choice for 
most centres, but follow-up testing and the indications to do so are variable. Intradermal testing 
appears to be under-used in comparison to international recommendations overall [1] [8] [9] and 
this was particularly so in paediatric centres. 
Chlorhexidine appeared to be under-investigated and not part of routine testing in many centres, in 
spite of its ubiquitous (and at times unrecognised) presence in the perioperative environment. 
Despite many publications and a suspicion of increasing prevalence of this potentially hidden 
allergen, many centres did not screen routinely, although all claimed to assess potential exposures. 
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No guideline explicitly states that chlorhexidine testing is mandatory in the investigation of 
perioperative anaphylaxis, but the variability in testing and the ubiquity of chlorhexidine make this 
worthy of consideration.  In contrast, latex allergy may be becoming less prevalent, yet is still 
routinely included by most. 
&ƌŽŵĂƉĂƚŝĞŶƚ ?ƐĂŶĚcůŝŶŝĐŝĂŶ ?Ɛperspective, variability of care is a concern.  Our patient 
representative authors were concerned about low-volume services that rarely see this type of event, 
or services that do not have harmonized protocols in place for testing of culprit agents and safe 
alternatives.  It was reassuring that no major differences were noted that obviously correlated with 
service size other than breadth of NMBA panel and fewer MDT discussions.  However, this survey did 
not evaluate differences in the diagnostic accuracy or quality of advice provided by centres, more 
data on this will be available through NAP6 data analysis. Therefore, the recommendations 
regarding hub and spoke networking to improve harmonisation and quality assurance merit 
consideration.  As recommended in NICE CG183 [3], it was noted that consultant-to-consultant 
referrals remain an important source of referral.  
This survey provides an important snapshot of UK provision and practice in perioperative allergy 
testing before the main phases of NAP6. 
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